Volume growth of AMGN's key drugs like Evenity, Repatha and Kyprolis is expected to have been partially offset by biosimilar/generic competition for mature drugs.
THOUSAND OAKS, Calif. , April 28, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets.
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
![]() AMGN In 2 weeks Announced | Quarterly | $2.38 Per Share |
![]() AMGN 2 months ago Paid | Quarterly | $2.38 Per Share |
![]() AMGN 5 months ago Paid | Quarterly | $2.25 Per Share |
![]() AMGN 8 months ago Paid | Quarterly | $2.25 Per Share |
![]() AMGN 11 months ago Paid | Quarterly | $2.25 Per Share |
30 Apr 2025 (1 Days) Date | | - Cons. EPS | - EPS |
4 Feb 2025 Date | | 5.08 Cons. EPS | 5.31 EPS |
30 Oct 2024 Date | | 5.11 Cons. EPS | 5.58 EPS |
29 Oct 2024 Date | | - Cons. EPS | - EPS |
8 Aug 2024 Date | | 5 Cons. EPS | - EPS |
![]() AMGN In 2 weeks Announced | Quarterly | $2.38 Per Share |
![]() AMGN 2 months ago Paid | Quarterly | $2.38 Per Share |
![]() AMGN 5 months ago Paid | Quarterly | $2.25 Per Share |
![]() AMGN 8 months ago Paid | Quarterly | $2.25 Per Share |
![]() AMGN 11 months ago Paid | Quarterly | $2.25 Per Share |
30 Apr 2025 (1 Days) Date | | - Cons. EPS | - EPS |
4 Feb 2025 Date | | 5.08 Cons. EPS | 5.31 EPS |
30 Oct 2024 Date | | 5.11 Cons. EPS | 5.58 EPS |
29 Oct 2024 Date | | - Cons. EPS | - EPS |
8 Aug 2024 Date | | 5 Cons. EPS | - EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Mr. Robert A. Bradway CEO | NASDAQ (NGS) Exchange | 031162100 Cusip |
United States Country | 26,700 Employees | 16 May 2025 Last Dividend | 22 Nov 1999 Last Split | 17 Jun 1983 IPO Date |
Amgen Inc. is a global leader in biotechnology, focusing on the discovery, development, manufacture, and delivery of human therapeutics. The company has a comprehensive portfolio of treatment options targeting various diseases and conditions, ranging from oncology and osteoporosis to cardiovascular diseases and inflammatory disorders. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen serves healthcare providers worldwide, including physicians' clinics, dialysis centers, hospitals, and pharmacies. Its distribution network encompasses pharmaceutical wholesale distributors and direct-to-consumer channels. Amgen’s collaborative efforts extend to several high-profile partnerships with other pharmaceutical giants, including AstraZeneca, Novartis Pharma AG, UCB, Kyowa Kirin Co., Ltd., and BeiGene, Ltd., aiming at the expansion and development of innovative therapies.